{"id":816915,"date":"2025-01-04T02:14:05","date_gmt":"2025-01-04T08:14:05","guid":{"rendered":"https:\/\/newsycanuse.com\/index.php\/2025\/01\/04\/weight-loss-drugs-seem-to-be-driving-down-grocery-bills\/"},"modified":"2025-01-04T02:14:05","modified_gmt":"2025-01-04T08:14:05","slug":"weight-loss-drugs-seem-to-be-driving-down-grocery-bills","status":"publish","type":"post","link":"https:\/\/newsycanuse.com\/index.php\/2025\/01\/04\/weight-loss-drugs-seem-to-be-driving-down-grocery-bills\/","title":{"rendered":"Weight loss drugs seem to be driving down grocery bills"},"content":{"rendered":"
\n
\n
In This Story<\/h6>\n<\/section>\n

GLP-1 drugs are driving down grocery spending<\/a><\/span>, according to a new study<\/a><\/span> from Cornell\u2019s SC Johnson College of Business and consumer data firm Numerator.<\/p>\n

\n

Suggested Reading<\/h4>\n<\/div>\n
\n
\n

Investors to AI firms: \u2018Show me the money\u2019\u2014Why ROI will dominate 2025<\/p>\n<\/div>\n

\n

Suggested Reading<\/h4>\n<\/div>\n

The study, which analyzed U.S. household transaction data over two years, found that households with at least one GLP-1 user reduced their grocery spending by about 6% within six months of starting the medication. High-income households, in particular, saw a reduction of nearly 9%. GLP-1 agonists include Ozempic, Wegovy, and Zepbound, yet only the latter two medications are approved by the FDA for weight management.<\/p>\n

What\u2019s driving the shift? Consumers are ditching calorie-dense processed foods like savory snacks and turning to healthier options such as fresh produce and yogurt. The savory snacks category alone saw an 11% drop, with spending on chips, sweet baked goods, and cookies seeing some of the largest declines. <\/p>\n

As a result, some consumers\u2019 grocery baskets have become more nutritious, the report notes. <\/p>\n

As adoption increases, the impact of these weight-loss drugs is extending beyond grocery stores<\/a><\/span>. The study also found reduced spending at fast-food chains and coffee shops, particularly during breakfast and dinner hours. Higher-income households were more likely to cut back on breakfast, while lower-income households made more significant reductions in dinner spending. <\/p>\n

The changes in consumer behavior following GLP-1 adoption are already being felt by the food industry. Major food companies, such as Kraft Heinz (KHC+0.15%<\/span><\/svg><\/span><\/span><\/span><\/a><\/span>) and Campbell\u2019s<\/a><\/span>, have reported sales declines, especially in processed foods and snacks. In response, these companies are diversifying their product lines<\/a><\/span> to cater to health-conscious consumers. For example, confectionary king Mars<\/a><\/span>\u00a0acquired Kevin\u2019s Natural Foods<\/a><\/span>, reflecting the growing demand for nutritious options driven by the popularity of GLP-1 medications. Meanwhile, Walmart\u2019s (WMT+0.82%<\/span><\/svg><\/span><\/span><\/span><\/a><\/span>) CEO Doug McMillion acknowledged \u201cmargin pressure\u201d due to the rise in GLP-1 use<\/a><\/span> during the company\u2019s Nov. 19 earnings call<\/a><\/span>. <\/p>\n

As GLP-1 adoption continues to grow, retailers and food manufacturers will need to adapt to these new consumer trends<\/a><\/span>. This could mean introducing additional items<\/a><\/span>, changing packing sizes, and adjusting market strategies<\/a><\/span>. The report notes that to stay competitive, companies must prioritize healthier products and make them more accessible to a wider audience. The shift toward fresh, nutrient-dense foods is no longer a passing trend \u2013 it\u2019s a key factor shaping the future of food<\/a><\/span>. Retailers and food producers that adapt quickly will be best positioned to meet the rapidly changing needs of consumers.<\/p>\n

This story was updated Jan. 3 to clarify that, while Wegovy and Ozempic are both prescribed for weight loss, only the former is approved by the FDA for such treatment.<\/em><\/p>\n<\/div>\n

Read More<\/a>
\n Francisco Velasquez<\/p>\n","protected":false},"excerpt":{"rendered":"

In This Story GLP-1 drugs are driving down grocery spending , according to a new study from Cornell\u2019s SC Johnson College of Business and consumer data firm Numerator. Suggested Reading Investors to AI firms: \u2018Show me the money\u2019\u2014Why ROI will dominate 2025 Suggested Reading The study, which analyzed U.S. household transaction data over two years<\/p>\n","protected":false},"author":1,"featured_media":816916,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22899,24791],"tags":[],"class_list":{"0":"post-816915","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-drugs","8":"category-weight"},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/816915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/comments?post=816915"}],"version-history":[{"count":0,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/816915\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media\/816916"}],"wp:attachment":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media?parent=816915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/categories?post=816915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/tags?post=816915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}